Release Date: Friday, June 11, 2021      Expiration Date: Saturday, June 11, 2022


Infections caused by multidrug-resistant (MDR) Gram-negative bacteria continue to challenge clinicians and are responsible for substantial morbidity and mortality. Timely administration of appropriate antimicrobial therapy is a major predictor of clinical outcomes. Infectious Disease specialists are knowledgeable on the characteristics of available antimicrobials, including pharmacokinetics/ pharmacodynamics, spectrum of activity, dosing and administration, and safety profiles, but rather than memorizing facts and information about antimicrobial agents, a more effective approach to care involves having a thorough understanding of the disease and following a conceptual framework to make decisions based on the available information. As such, concept maps have been proposed to guide treatment selection based on the information gathered for each patient situation. Antimicrobial ‘precision medicine’ is increasingly possible now with the availability of advanced tools that provide timely information about the patient and pathogen to make clinical decisions. 



At the conclusion of the educational activity, the learner should be able to:

  • Apply knowledge of local epidemiological trends and resistance mechanisms of Gram-negative bacteria to guide initial antimicrobial selection
  • Evaluate the potential role of newer and novel antimicrobial agents in targeting antimicrobial-resistant Gram-negative pathogens
  • Implement a concept map approach when making clinical decisions for serious bacterial infections based on causative organism, epidemiology, and patient factors


This activity meets the needs of pharmacists, physicians and other healthcare professionals in a variety of practice settings, including large and small healthcare systems, outpatient clinics, managed care organizations, long-term care facilities, and academia who are responsible for caring for patients with serious bacterial infections. 



This program is designed to introduce clinicians to the concept map approach to address key unmet needs when managing serious Gram-negative bacterial infections, such as timely diagnosis, appropriate initial treatment selection, and assessing outcomes. Topics to be discussed via a collaborative discussion among the expert panel include:

  • Gram-negative resistance mechanisms
  • Impact of local epidemiology
  • Clinical data of newer antimicrobials targeting MDR Gram-negative bacteria
  • Patient stratification to guide treatment selection
  • Pathogen-specific approaches when managing nosocomial pneumonia
  • Incorporating concept maps in clinical practice


George H. Karam, MD, MACP
Paula Garvey Manship Chair of Medicine
Department of Medicine
Louisiana State University School of Medicine in New Orleans
Baton Rouge Branch Campus
Baton Rouge, LA

Jason M. Pogue, PharmD, BCPS, BCIDP
Clinical Professor
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Ann Arbor, MI



Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credits for participating in this activity.
ACPE UAN: 0473-9999-21-004-H01-P
Activity type: Application-based


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Center designates this Enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

Nurse Practitioners
Nurse Practitioners will receive certificate of AMA PRA Category 1 Credit™ as this is an ACCME accredited program and its accreditation is recognized by Nurse Practitioner boards.

For questions regarding the accreditation of this activity, please contact us at

Method of Participation and Instruction for Credit

  1. Review the entire CME/CPE information including target audience, learning objectives, and disclosures.
  2. Review the activity in its entirety.
  3. Complete the Online Post Test, Evaluation, and Credit Application form
  4. Please note that to receive credit you must achieve a score of at least 70%.
  5. Pharmacists: The information that you participated will be uploaded to CPEMonitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit
  6. Physicians: Certificate of Credit will be emailed to you within 4 weeks.

Disclosure of Financial Relationships with Ineligible Companies

Center for Independent Healthcare Education and Vemco MedEd fully comply with the Standards for Integrity and Independence in Accredited Continuing Education in development of CME/CPE activities. We require the full disclosure of financial relationships with ineligible companies from all individuals in a position to influence the content of a certified activity, in any amount occurring within the past 24 months.

All relevant financial relationships are identified by the provider and mitigated to prevent inserting commercial bias into content. All identified relevant financial relationships are disclosed to the learners prior to the activity. The faculty is further required to disclose discussion of off-label uses in their presentations.



George Karam, MD has relevant financial relationships with ineligible companies to disclose:
▪ Advisory Board: Merck & Co., Inc.
▪ Consultant: Merck & Co., Inc., Shionogi Inc.
All relevant financial relationships have been mitigated.
Dr. Karam does not discuss the off-label use of a product.

Jason Pogue, PharmD has relevant financial relationships with ineligible companies to disclose:
▪ Consultant: Merck & Co., Inc., Melinta Therapeutics, Shionogi Inc., Qpex
All relevant financial relationships have been mitigated.
Dr. Pogue does not discuss the off-label use of a product.

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose. Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2021 Vemco MedEd. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support
This activity is supported by an educational grant from Merck & Co., Inc.


By clicking on the activity icon below, I acknowledge that I have read the entire CME/CPE information.